Donepezil
Small molecule targets ACHE via inhibition
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Refused (EMA) | EU (EMA) | Balaxur | — | 2013-02-20 | europa.eu ↗ |
| Label expansion | US (FDA) | ARICEPT ODT | — | 2006-10-13 | fda.gov ↗ |
| Approved | US (FDA) | ARICEPT | — | 1996-11-25 | fda.gov ↗ |
Trials 191 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 04 trials | ||||||
| Phase 0 | NCT05438264 | Mar 2023 → Sep 2026 expected | sensorineural hearing loss disorder | Vanderbilt University Medical Center | Active not recruiting | No outcome recorded |
| Phase 0 | NCT05540977 | Aug 2022 → May 2023 | — | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Unknown | No outcome recorded |
| Phase 0 | NCT03599726 | Jul 2018 → May 2019 | Parkinson disease | Oregon Health and Science University | Completed | No outcome recorded |
| Phase 0 | NCT00452868 | Jun 2006 → Feb 2010 | central nervous system neoplasm, chemotherapy-induced toxicity, cognitive disorder, radiation-induced disorder | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 155 trials | ||||||
| Phase 1 | NCT06373094 | Jun 2024 → Mar 2025 | Alzheimer disease | Shanghai Synergy Pharmaceutical Sciences Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT06127368 | Jan → Sep 2024 | Alzheimer disease | G2GBio, Inc. | Unknown | No outcome recorded |
| Phase 1 | NCT05804279 | Dec 2022 → Feb 2023 | — | Hyundai Pharm | Completed | No outcome recorded |
| Phase 1 | NCT05525780 | Aug 2022 → Jun 2023 | Alzheimer disease | G2GBio, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05136690 | Apr → Sep 2022 | schizophrenia | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT05127746 | Nov 2021 → Dec 2022 | — | Dong-A ST Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04730635 | Mar 2021 → Jan 2023 | Alzheimer disease, cognitive impairment with or without cerebellar ataxia | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT04308304 | Feb 2021 → May 2022 | Alzheimer disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT04479865 | Jul → Dec 2020 | — | Dong-A ST Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT03740178 | Sep 2019 → Feb 2020 | Alzheimer disease, cognitive impairment with or without cerebellar ataxia | Merck Sharp & Dohme LLC | Withdrawn | No outcome recorded |
| Phase 1 | NCT03905096 | Apr → Aug 2019 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03569579 | Apr → May 2018 | central nervous system disorder | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT03438604 | Feb → Jun 2018 | Alzheimer disease | Corium, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03432195 | Jan → Jun 2018 | Alzheimer disease | Corium, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03397862 | Nov 2017 → Mar 2018 | skin disorder | Corium, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03030105 | Jan → May 2017 | Alzheimer disease | Tetra Discovery Partners | Completed | No outcome recorded |
| Phase 1 | NCT02918266 | Nov 2016 → Aug 2017 | — | Takeda | Terminated | No outcome recorded |
| Phase 1 | NCT02968719 | Nov 2016 → Jul 2017 | Alzheimer disease | Corium, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02769065 | May 2016 → Jun 2017 | Alzheimer disease | Takeda | Terminated | No outcome recorded |
| Phase 1 | NCT02695004 | Feb 2016 → Mar 2017 | Alzheimer disease | Dongkook Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02635750 | Jan → Mar 2016 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02406261 | Apr → Aug 2015 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02225288 | Sep → Dec 2014 | — | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02178124 | Jul → Dec 2014 | Alzheimer disease | Icure Pharmaceutical Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02055703 | Jan → Apr 2014 | — | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02051335 | Jan → May 2014 | Alzheimer disease | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01903824 | Aug → Oct 2013 | cognitive disorder | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01860625 | Apr → Dec 2013 | Alzheimer disease | Icure Pharmaceutical Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01843556 | Dec 2012 → Apr 2013 | — | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02042729 | Aug → Oct 2012 | — | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01584076 | Aug 2012 → Jan 2021 | amblyopia | Boston Children's Hospital | Completed | No outcome recorded |
| Phase 1 | NCT01461174 | Nov 2011 → Nov 2014 | — | Qualissima | Completed | No outcome recorded |
| Phase 1 | NCT01485185 | Oct 2011 → Jul 2012 | neuropathy, painful | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01450839 | Sep → Nov 2011 | — | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01345864 | May → Jul 2011 | — | Pfizer | Terminated | No outcome recorded |
| Phase 1 | NCT01253434 | Nov 2010 → Mar 2011 | — | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01923259 | Oct 2010 | — | Dr. Reddy's Laboratories Limited | Completed | No outcome recorded |
| Phase 1 | NCT01923558 | Oct 2010 | — | Dr. Reddy's Laboratories Limited | Completed | No outcome recorded |
| Phase 1 | NCT01097876 | Apr → Jul 2010 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01042314 | Jan → Apr 2010 | Alzheimer disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT00874939 | Apr 2009 | Alzheimer disease | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 1 | NCT00713765 | Dec 2008 | Alzheimer disease | AstraZeneca | Terminated | No outcome recorded |
| Phase 1 | NCT00777608 | Dec 2008 → Oct 2009 | Alzheimer disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT00750529 | Nov 2008 → Sep 2013 | Alzheimer disease | University Hospital, Clermont-Ferrand | Completed | No outcome recorded |
| Phase 1 | NCT00766363 | Oct 2008 → Mar 2009 | Alzheimer disease | FORUM Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT01297036 | Jan → Mar 2008 | Alzheimer disease | Korea University Anam Hospital | Completed | No outcome recorded |
| Phase 1 | NCT00887601 | Aug 2007 → May 2008 | dementia | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT01439230 | Jun → Aug 2007 | — | Teva Pharmaceuticals USA | Completed | No outcome recorded |
| Phase 1 | NCT01181310 | Jun → Oct 2007 | dementia | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT01439243 | Jun → Jul 2007 | — | Teva Pharmaceuticals USA | Completed | No outcome recorded |
| Phase 1 | NCT00457769 | May 2007 → Dec 2021 | stroke disorder, vascular dementia | Kessler Foundation | Unknown | No outcome recorded |
| Phase 1 | NCT00408525 | Dec 2006 → Aug 2012 | Alzheimer disease | Vanderbilt University | Completed | No outcome recorded |
| Phase 1 | NCT01260948 | Apr → May 2006 | — | Teva Pharmaceuticals USA | Completed | No outcome recorded |
| Phase 1 | NCT01260922 | Apr → May 2006 | — | Teva Pharmaceuticals USA | Completed | No outcome recorded |
| Phase 1 | NCT00220584 | Jul 2005 → Jul 2009 | fragile X syndrome | Stanford University | Completed | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT05345509 | Apr 2023 → Nov 2025 overdue | Alzheimer disease | Inventage Lab., Inc. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02696512 | Mar 2016 → Mar 2017 | brain injury | International Brain Research Foundation | Unknown | No outcome recorded |
| Phase 1/2 | NCT01442766 | Nov 2011 → Nov 2013 | stroke disorder | Imperial College London | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT00695136 | Jun 2008 → Jan 2011 | autism, cognitive disorder | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| Phase 237 trials | ||||||
| Phase 2 | NCT06518941 | Jun 2026 → Jun 2027 expected | anorexia nervosa | New York State Psychiatric Institute | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06041789 | Feb 2025 → Nov 2026 expected | osteoporosis | Duke University | Recruiting | No outcome recorded |
| Phase 2 | NCT06903910 | Nov 2024 → Jun 2025 | Parkinson disease | University of Virginia | Completed | No outcome recorded |
| Phase 2 | NCT06687993 | Nov 2024 → Feb 2030 expected | anorexia nervosa | Centre Hospitalier St Anne | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05709301 | Oct 2023 → Nov 2025 | Parkinson disease, cognitive impairment with or without cerebellar ataxia | Sant Pau Research Institute | Unknown | No outcome recorded |
| Phase 2 | NCT05042102 | Aug 2022 → Oct 2026 expected | alcohol-related disorders | VA Connecticut Healthcare System | Recruiting | No outcome recorded |
| Phase 2 | NCT05254639 | Jun 2022 → Jan 2024 | digestive system cancer | University Hospital, Clermont-Ferrand | Completed | No outcome recorded |
| Phase 2 | NCT04505670 | Aug 2020 → Jul 2023 | — | University of Maryland, Baltimore | Unknown | No outcome recorded |
| Phase 2 | NCT04507438 | Jul 2019 → Sep 2023 | type 2 diabetes mellitus | University of Maryland, Baltimore | Terminated | No outcome recorded |
| Phase 2 | NCT03907371 | May 2019 → Dec 2022 | cognitive disorder, radiation-induced disorder | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Unknown | No outcome recorded |
| Phase 2 | NCT02857244 | Nov 2016 → Nov 2017 | Parkinson disease | University of Chicago | Withdrawn | No outcome recorded |
| Phase 2 | NCT02860065 | Sep 2016 → Jun 2017 | Alzheimer disease | Chase Pharmaceuticals Corporation, an affiliate of Allergan plc | Withdrawn | No outcome recorded |
| Phase 2 | NCT02549196 | Oct 2015 → Sep 2017 | Alzheimer disease | Chase Pharmaceuticals Corporation, an affiliate of Allergan plc | Completed | No outcome recorded |
| Phase 2 | NCT02415062 | Jul 2015 → Oct 2016 | Parkinson disease | Inje University | Unknown | No outcome recorded |
| Phase 2 | NCT02450786 | Jun 2015 → Aug 2019 | Parkinson disease | Yonsei University | Unknown | No outcome recorded |
| Phase 2 | NCT02487082 | Jun 2015 → Dec 2020 | autism spectrum disorder | Stony Brook University | Terminated | No outcome recorded |
| Phase 2 | NCT02206620 | Jul 2014 → Jul 2017 | Parkinson disease | Oregon Health and Science University | Completed | No outcome recorded |
| Phase 2 | NCT02064920 | Apr 2014 → Jul 2016 | Alzheimer disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT02094053 | Sep 2013 → Sep 2016 | Down syndrome | Eisai Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01887132 | Jun 2013 → Dec 2015 | autism spectrum disorder | National Institute of Mental Health (NIMH) | Terminated | No outcome recorded |
| Phase 2 | NCT01466270 | Jul 2012 → Oct 2013 | anxiety disorder, breast cancer, cognitive disorder, depressive disorder +1 | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 2 | NCT01495195 | Feb 2012 → May 2013 | substance-related disorder | Midwest Biomedical Research Foundation | Completed | No outcome recorded |
| Phase 2 | NCT01250977 | Jan → Dec 2011 | — | Abramson Cancer Center at Penn Medicine | Completed | No outcome recorded |
| Phase 2 | NCT00916383 | May → Jun 2009 | irritant dermatitis | Teikoku Pharma USA, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00805792 | Nov 2008 → Sep 2010 | ischemic stroke | Mayo Clinic | Completed | No outcome recorded |
| Phase 2 | NCT00675025 | Apr → Nov 2008 | Down syndrome | Eisai Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT00598650 | Feb 2008 → Mar 2011 | Lewy body dementia | Eisai Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00543855 | Nov 2007 → Feb 2010 | Lewy body dementia | Eisai Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00467389 | Feb 2007 → Sep 2008 | cocaine dependence | US Department of Veterans Affairs | Completed | No outcome recorded |
| Phase 2 | NCT00348192 | May 2006 → ? | Alzheimer disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00103948 | Feb 2005 → Oct 2006 | cognitive impairment with or without cerebellar ataxia | Eisai Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00911807 | Oct 2004 → Apr 2008 | Alzheimer disease | Ever Neuro Pharma GmbH | Completed | No outcome recorded |
| Phase 2 | NCT01146509 | Jan 2003 → Apr 2004 | migraine disorder | Eisai Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00165659 | Nov 2002 → May 2005 | Alzheimer disease | Eisai Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00047697 | Oct 2002 → Aug 2006 | autism | University of Pittsburgh | Completed | No outcome recorded |
| Phase 2 | NCT00070161 | Jul 2001 → May 2005 | central nervous system neoplasm, radiation-induced disorder | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 2 | NCT00139373 | — | progressive supranuclear palsy | Groupe Hospitalier Pitie-Salpetriere | Unknown | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT04318639 | Aug 2018 → Dec 2019 | alcohol-related disorders, cognitive impairment with or without cerebellar ataxia | VA Connecticut Healthcare System | Completed | No outcome recorded |
| Phase 2/3 | NCT03090516 | Aug 2016 → Mar 2020 | Alzheimer disease | The First Affiliated Hospital with Nanjing Medical University | Unknown | No outcome recorded |
| Phase 2/3 | NCT02248636 | Jan 2015 → Oct 2019 | dementia | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 326 trials | ||||||
| Phase 3 | NCT04661280 | Feb 2022 → Aug 2026 overdue | — | Assistance Publique - Hôpitaux de Paris | Recruiting | No outcome recorded |
| Phase 3 | NCT04134416 | Jan 2019 → Oct 2020 | aphasia, stroke disorder | University of Malaga | Completed | No outcome recorded |
| Phase 3 | NCT02927522 | Sep 2018 → Dec 2021 | avascular necrosis, osteoarthritis, rheumatoid arthritis | RenJi Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT03197740 | Oct 2017 → Jul 2020 | Alzheimer disease | Icure Pharmaceutical Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02374567 | Jan 2015 → Jun 2017 | anxiety disorder, dementia, depressive disorder, schizophrenia +1 | Hannover Medical School | Terminated | No outcome recorded |
| Phase 3 | NCT02550665 | Dec 2014 → Aug 2016 | Alzheimer disease | Asan Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT01014858 | Jan 2013 → Sep 2014 | Parkinson disease | Newcastle-upon-Tyne Hospitals NHS Trust | Terminated | No outcome recorded |
| Phase 3 | NCT01404169 | Sep 2011 → Jul 2014 | Alzheimer disease | Eisai Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01278407 | Feb 2011 → Mar 2013 | Lewy body dementia | Eisai Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00868010 | Mar 2009 → Aug 2013 | ischemic stroke | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Unknown | No outcome recorded |
| Phase 3 | NCT00688376 | Jul 2008 → May 2009 | cognitive impairment with or without cerebellar ataxia | Eisai Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00369785 | Feb 2008 → Jul 2012 | brain neoplasm, metastatic neoplasm | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 3 | NCT00566501 | Dec 2007 → Apr 2010 | Alzheimer disease | Eisai Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00478205 | Jun 2007 → Jun 2009 | Alzheimer disease | Eisai Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00174382 | Jun 2005 → Apr 2008 | vascular dementia | Pfizer | Terminated | No outcome recorded |
| Phase 3 | NCT00069550 | Sep 2004 → Jun 2008 | Rett syndrome | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Unknown | No outcome recorded |
| Phase 3 | NCT00188812 | May 2004 → Aug 2005 | vascular dementia | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 3 | NCT01327859 | Mar 2003 → Jul 2006 | Parkinson disease, dementia | Eisai Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00165737 | Mar 2003 → Aug 2005 | vascular dementia | Eisai Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00630851 | Oct 2002 → Oct 2004 | Alzheimer disease | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00165815 | Aug 2002 → Jul 2005 | Parkinson disease | Eisai Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00006349 | Feb 2001 → Jan 2005 | delirium, depressive disorder, radiation-induced disorder, small cell lung carcinoma | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 3 | NCT00096473 | Jan 2001 → Jun 2005 | Alzheimer disease | Eisai Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00062972 | Sep 1999 → Aug 2002 | multiple sclerosis | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Withdrawn | No outcome recorded |
| Phase 3 | NCT00000173 | Mar 1999 → Jan 2004 | Alzheimer disease | National Institute on Aging (NIA) | Completed | No outcome recorded |
| Phase 3 | NCT00190021 | — | Alzheimer disease | Beersheva Mental Health Center | Unknown | No outcome recorded |
| Phase 447 trials | ||||||
| Phase 4 | NCT03454646 | Jun 2024 → Apr 2027 expected | Alzheimer disease | University Hospital, Bordeaux | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07153991 | Nov 2021 → Dec 2025 overdue | tinnitus | University of Sao Paulo | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04423276 | Jun 2020 → Dec 2021 | vertebral column disorder | RenJi Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT04117178 | Feb 2020 → Feb 2023 | Alzheimer disease, Lewy body dementia, Parkinson disease | Zealand University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02787746 | Apr 2016 → Jan 2019 | Alzheimer disease | Beijing Friendship Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02345213 | Mar 2015 → May 2017 | Lewy body dementia | Eisai Inc. | Completed | No outcome recorded |
| Phase 4 | NCT02264353 | Sep 2014 → May 2015 | obstructive sleep apnea syndrome | University of California, San Diego | Completed | No outcome recorded |
| Phase 4 | NCT02097056 | Feb 2014 → May 2015 | Alzheimer disease | Eisai Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT01951118 | Oct 2013 → May 2019 | Alzheimer disease, cognitive impairment with or without cerebellar ataxia | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 4 | NCT02660983 | Aug 2013 → Jul 2018 | vascular dementia | Eisai Inc. | Completed | No outcome recorded |
| Phase 4 | NCT01743976 | Dec 2012 → Oct 2013 | neuropathy, painful | Wake Forest University | Terminated | No outcome recorded |
| Phase 4 | NCT01845636 | Aug 2012 → Mar 2016 | cognitive impairment with or without cerebellar ataxia | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 4 | NCT01633593 | Aug 2012 → Dec 2015 | delirium, myopathy | University of Sao Paulo | Terminated | No outcome recorded |
| Phase 4 | NCT01521117 | Dec 2011 → Apr 2012 | Parkinson disease | Oregon Health and Science University | Completed | No outcome recorded |
| Phase 4 | NCT01658228 | Sep 2011 → Jan 2016 | cognitive impairment with or without cerebellar ataxia, depressive disorder | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 4 | NCT01098383 | Mar 2010 → Dec 2017 | autism | Sheba Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT01063556 | Feb → Mar 2010 | end stage renal failure | Eisai Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00571064 | Jan → Dec 2008 | Alzheimer disease | Eisai Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00477659 | Jul 2007 → Aug 2008 | Alzheimer disease | Eisai Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00482001 | Jun 2007 → Aug 2008 | mental disorder | Sunnybrook Health Sciences Centre | Completed | No outcome recorded |
| Phase 4 | NCT00912457 | Mar 2007 → Dec 2009 | obstructive sleep apnea syndrome | Associacao Fundo de Incentivo a Psicofarmcologia | Unknown | No outcome recorded |
| Phase 4 | NCT00800553 | Nov 2006 → May 2007 | — | Duke-NUS Graduate Medical School | Completed | No outcome recorded |
| Phase 4 | NCT00403520 | Nov 2006 → Mar 2008 | Alzheimer disease | Eisai Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00369603 | Oct 2006 → Oct 2007 | Alzheimer disease | Duke University | Terminated | No outcome recorded |
| Phase 4 | NCT00381381 | May 2006 → Aug 2008 | Alzheimer disease | Eisai Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT00934375 | Feb 2006 → Sep 2007 | cognitive impairment with or without cerebellar ataxia | Eisai Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00220896 | Jan 2006 → Mar 2009 | — | Technical University of Munich | Completed | No outcome recorded |
| Phase 4 | NCT03073876 | Dec 2005 → Jul 2009 | Alzheimer disease | NYU Langone Health | Completed | No outcome recorded |
| Phase 4 | NCT00230568 | Dec 2005 → Apr 2007 | Alzheimer disease | Eisai Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00165763 | Sep 2005 → Sep 2009 | vascular dementia | Eisai Inc. | Completed | No outcome recorded |
| Phase 4 | NCT01191918 | May 2005 → Apr 2008 | manic bipolar affective disorder | Shanghai Mental Health Center | Completed | No outcome recorded |
| Phase 4 | NCT00165750 | Mar 2005 → Aug 2008 | Alzheimer disease | Eisai Co., Ltd. | Terminated | No outcome recorded |
| Phase 4 | NCT00182845 | Feb 2005 → Apr 2007 | delirium | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00315367 | Sep 2004 → Oct 2007 | relapsing-remitting multiple sclerosis | Neurognostics | Completed | No outcome recorded |
| Phase 4 | NCT00182884 | Jul 2004 → Apr 2007 | delirium | Indiana University Health | Completed | No outcome recorded |
| Phase 4 | NCT00165724 | Jun 2004 → Jul 2006 | Alzheimer disease | Eisai Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT00293176 | Dec 2003 → Mar 2007 | amnestic disorder | Eisai Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00177671 | Dec 2003 → Sep 2009 | dementia, major depressive disorder | University of Pittsburgh | Completed | No outcome recorded |
| Phase 4 | NCT00142324 | Nov 2003 → Dec 2005 | Alzheimer disease | Institute of Psychiatry, London | Unknown | No outcome recorded |
| Phase 4 | NCT00227994 | Apr 2003 → Jan 2005 | stroke disorder | University of Pittsburgh | Completed | No outcome recorded |
| Phase 4 | NCT00196690 | Feb 2003 → Mar 2005 | aphasia, stroke disorder | Gabinete Berthier y Martínez | Completed | No outcome recorded |
| Phase 4 | NCT00042172 | Jun 2002 → Sep 2004 | Alzheimer disease | University of Iowa | Completed | No outcome recorded |
| Phase 4 | NCT00030979 | Feb 2002 → Mar 2005 | Parkinson disease | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | No outcome recorded |
| Phase 4 | NCT00267163 | Sep 2000 → Jul 2007 | cognitive disorder | National Institute on Aging (NIA) | Completed | No outcome recorded |
| Phase 4 | NCT02988908 | Apr 2000 → Sep 2007 | — | Stanford University | Completed | No outcome recorded |
| Phase 4 | NCT00480870 | Apr 1999 → Jan 2005 | Alzheimer disease, obstructive sleep apnea syndrome | Associacao Fundo de Incentivo a Psicofarmcologia | Completed | No outcome recorded |
| Phase 4 | NCT00018278 | Oct 1998 → Sep 2001 | Alzheimer disease | US Department of Veterans Affairs | Completed | No outcome recorded |
| Phase not applicable15 trials | ||||||
| — | NCT07680660 | Jul 2026 → Sep 2028 expected | Alzheimer disease | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Not yet recruiting | No outcome recorded |
| — | NCT05641480 | Jun 2022 → Dec 2025 | Alzheimer disease, cognitive impairment with or without cerebellar ataxia, subjective cognitive decline | Shaanxi Hospital of Traditional Chinese Medicine | Unknown | No outcome recorded |
| — | NCT01362686 | Apr 2011 → Oct 2015 | Alzheimer disease | Indiana University | Terminated | No outcome recorded |
| — | NCT01082965 | Jul 2010 → Jul 2012 | Alzheimer disease | Pfizer | Terminated | No outcome recorded |
| — | NCT00934531 | Sep 2009 → Jan 2019 | cognitive impairment with or without cerebellar ataxia | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Completed | No outcome recorded |
| — | NCT00776347 | Oct 2008 → Feb 2015 | Lewy body dementia | Osaka University | Completed | No outcome recorded |
| — | NCT01379001 | Jul 2008 → Jan 2013 | — | Hebrew SeniorLife | Completed | No outcome recorded |
| — | NCT01023425 | Feb 2008 → Apr 2009 | Alzheimer disease | Samsung Medical Center | Completed | No outcome recorded |
| — | NCT00533065 | Sep 2007 → Jul 2009 | — | Ludwig Boltzmann Gesellschaft | Completed | No outcome recorded |
| — | NCT01023867 | Mar 2007 → Jun 2010 | Alzheimer disease | Samsung Medical Center | Completed | No outcome recorded |
| — | NCT00912808 | Oct 2005 → Feb 2009 | Parkinson disease | Oregon Health and Science University | Completed | No outcome recorded |
| — | NCT00483028 | Jun 2004 → Jan 2007 | Alzheimer disease | Pfizer | Completed | No outcome recorded |
| — | NCT00043589 | Jun 2002 → Dec 2006 | amnestic disorder | Stanford University | Completed | No outcome recorded |
| — | NCT00004807 | Jan 1995 → ? | Rett syndrome | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Completed | No outcome recorded |
| — | NCT00530478 | — | stroke disorder | Samsung Medical Center | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 96 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 04 trials | ||||||
| Phase 0 | NCT07208344 Background | Jul → Dec 2025 overdue | Alzheimer disease | Anhui Provincial Hospital | Recruiting | No outcome recorded |
| Phase 0 | NCT06393413 Comparator | Dec 2022 → Dec 2023 | — | Changchun University of Chinese Medicine | Completed | No outcome recorded |
| Phase 0 | NCT05003063 Comparator | Feb → Aug 2021 | — | University of California, Berkeley | Completed | No outcome recorded |
| Phase 0 | NCT01024660 Comparator | Dec 2009 → Jan 2011 | Alzheimer disease | AstraZeneca | Completed | No outcome recorded |
| Phase 114 trials | ||||||
| Phase 1 | NCT06774261 Comparator | Feb → Dec 2025 | Alzheimer disease, cognitive impairment with or without cerebellar ataxia | Helse Stavanger HF | Completed | No outcome recorded |
| Phase 1 | NCT07094438 Comparator | Jan 2025 → Jun 2026 overdue | Alzheimer disease | Chinese PLA General Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT06285240 Background | Mar → Sep 2024 | Alzheimer disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT04617782 Comparator | Dec 2020 → Apr 2021 | — | Corium, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03932916 Comparator | Jul 2019 → Aug 2020 | — | Shanghai Synergy Pharmaceutical Sciences Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04013477 Comparator | Jun → Dec 2019 | — | Dong-A ST Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03802162 Comparator | Feb → May 2019 | Alzheimer disease | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT03316898 Background | Sep → Nov 2018 | Alzheimer disease | Allergan | Withdrawn | No outcome recorded |
| Phase 1 | NCT03698695 Comparator | Sep 2018 → Oct 2019 | Alzheimer disease, cognitive impairment with or without cerebellar ataxia | Theranexus | Completed | No outcome recorded |
| Phase 1 | NCT01487395 Comparator | Dec 2011 → Dec 2012 | Alzheimer disease | University Hospital, Lille | Completed | No outcome recorded |
| Phase 1 | NCT01213355 Comparator | Apr → Aug 2011 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01044342 Comparator | Dec 2009 → Apr 2010 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00959881 Background | Aug → Nov 2009 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00519298 Comparator | Oct 2007 → Mar 2008 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 231 trials | ||||||
| Phase 2 | NCT05538507 Comparator | Jun 2022 → Jun 2024 | Alzheimer disease, cognitive impairment with or without cerebellar ataxia | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT02305836 Comparator | Jun 2017 → Jun 2019 | cognitive disorder | Guang'anmen Hospital of China Academy of Chinese Medical Sciences | Unknown | No outcome recorded |
| Phase 2 | NCT03055741 Background | Dec 2016 → Feb 2019 | Alzheimer disease | Daehwa Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT01255046 Comparator | Dec 2015 → Dec 2018 | Alzheimer disease | Sinphar Pharmaceutical Co., Ltd | Unknown | No outcome recorded |
| Phase 2 | NCT02580305 Comparator | Sep 2015 → Nov 2019 | Alzheimer disease | Suven Life Sciences Limited | Completed | No outcome recorded |
| Phase 2 | NCT02337907 Comparator | Jan 2015 → Sep 2017 | Alzheimer disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT02222727 Comparator | Jan 2014 → Nov 2016 | acquired aneurysmal subarachnoid hemorrhage, brain ischemia, intracranial vasospasm | St George's, University of London | Terminated | No outcome recorded |
| Phase 2 | NCT01852110 Background | Oct 2013 → Apr 2016 | Alzheimer disease | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 2 | NCT01677754 Background | Oct 2012 → Jun 2015 | Alzheimer disease | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT01527916 Comparator | Feb 2012 → Nov 2013 | Alzheimer disease | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT01466088 Comparator | Oct 2011 → May 2014 | Alzheimer disease | Targacept Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01266525 Background | Feb 2011 → Jan 2013 | Alzheimer disease | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT01276353 Comparator | Jan 2011 → Apr 2012 | Alzheimer disease | Eisai Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01125683 Comparator | Jun 2010 → Mar 2011 | Alzheimer disease | AstraZeneca | Terminated | No outcome recorded |
| Phase 2 | NCT01137526 Comparator | May 2010 → Jul 2011 | Alzheimer disease | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT01018875 Comparator | Dec 2009 → Feb 2011 | Alzheimer disease | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT00948909 Comparator | Oct 2009 → Nov 2010 | Alzheimer disease | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT01120626 Comparator | Sep 2009 → Dec 2013 | fragile X syndrome | Stanford University | Completed | No outcome recorded |
| Phase 2 | NCT00967707 Comparator | Aug 2009 → Apr 2011 | traumatic neuropathy | Uppsala University | Completed | No outcome recorded |
| Phase 2 | NCT00895895 Comparator | May 2009 → May 2011 | Alzheimer disease | Pfizer | Terminated | No outcome recorded |
| Phase 2 | NCT00708552 Comparator | Jul 2008 → Mar 2010 | Alzheimer disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00710684 Background | Jul 2008 → May 2010 | Alzheimer disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00693004 Comparator | May 2008 → Jan 2010 | Alzheimer disease | Epix Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT00602680 Comparator | Jan → Jul 2008 | Alzheimer disease | Sanofi | Terminated | No outcome recorded |
| Phase 2 | NCT00570128 Comparator | Nov 2007 → Sep 2008 | Down syndrome | Eisai Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00501111 Comparator | Jul 2007 → Aug 2008 | Alzheimer disease | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00586196 Comparator | Jan 2007 → Feb 2013 | delirium | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00151398 Comparator | Oct 2005 → Mar 2008 | Alzheimer disease | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00206947 Comparator | Dec 2002 → Jan 2005 | schizophrenia | Birte Glenthoj | Terminated | No outcome recorded |
| Phase 2 | NCT00006399 Background | Sep 1999 → Mar 2004 | Alzheimer disease | National Center for Research Resources (NCRR) | Completed | No outcome recorded |
| Phase 2 | NCT00031018 Background | — | Alzheimer disease | National Center for Research Resources (NCRR) | Unknown | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT07066826 Comparator | Aug 2025 → Aug 2028 expected | Alzheimer disease | Wanbangde Pharmaceutical Group Co., LTD | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT05811000 Comparator | Nov 2020 → Feb 2021 | Alzheimer disease | Mediforum Ltd., Co. | Unknown | No outcome recorded |
| Phase 315 trials | ||||||
| Phase 3 | NCT05564169 Background | Jun 2026 → Dec 2028 expected | Alzheimer disease | AB Science | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07060391 Comparator | Jul 2025 → Jan 2027 expected | Alzheimer disease | Shanghai Jiao Tong University School of Medicine | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT03283059 Comparator | Aug 2017 → Sep 2020 | Alzheimer disease | Shanghai Mental Health Center | Unknown | No outcome recorded |
| Phase 3 | NCT02822573 Comparator | May 2017 → Jul 2022 | amnestic disorder | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 3 | NCT02453932 Comparator | Oct 2013 → May 2017 | vascular dementia | Dongzhimen Hospital, Beijing | Completed | No outcome recorded |
| Phase 3 | NCT02255799 Comparator | Sep 2013 → Dec 2024 | traumatic brain injury | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 3 | NCT01940952 Comparator | Sep 2013 → Aug 2015 | Alzheimer disease | Samsung Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT01539031 Comparator | Mar 2012 → Jan 2015 | Alzheimer disease | Eisai Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01872598 Background | Jan 2012 → Dec 2020 | Alzheimer disease | AB Science | Completed | No outcome recorded |
| Phase 3 | NCT02035982 Comparator | Jul 2010 → May 2014 | Alzheimer disease | Sunnybrook Health Sciences Centre | Completed | No outcome recorded |
| Phase 3 | NCT00754013 Comparator | Sep → Oct 2008 | Down syndrome, cognitive disorder | Eisai Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT01451749 Comparator | Sep 2008 → May 2009 | cognitive impairment with or without cerebellar ataxia | North China Pharmaceutical Group Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00754052 Comparator | Sep → Nov 2008 | Down syndrome, cognitive disorder | Eisai Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT01245530 Comparator | Jun 2008 → Feb 2011 | Alzheimer disease | Whanin Pharmaceutical Company | Completed | No outcome recorded |
| Phase 3 | NCT00352664 Comparator | Nov 2003 → Jul 2007 | — | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 418 trials | ||||||
| Phase 4 | NCT07604896 Comparator | Jan 2026 → Dec 2027 expected | Alzheimer disease | First Affiliated Hospital of Wenzhou Medical University | Recruiting | No outcome recorded |
| Phase 4 | NCT03954613 Background | Oct 2020 → Mar 2023 | Alzheimer disease | Neutec Ar-Ge San ve Tic A.Ş | Unknown | No outcome recorded |
| Phase 4 | NCT03299257 Comparator | Jul → Nov 2018 | hypersomnia, obstructive sleep apnea syndrome | Associação Fundo de Incentivo à Pesquisa | Unknown | No outcome recorded |
| Phase 4 | NCT03441516 Comparator | Apr 2018 → Jul 2019 | Alzheimer disease | Yuhan Corporation | Unknown | No outcome recorded |
| Phase 4 | NCT03151382 Background | May → Dec 2017 | Alzheimer disease | Zhejiang Provincial People's Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03011476 Comparator | Apr 2017 → Oct 2018 | Parkinson disease | Kyung Hee University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02670161 Comparator | May 2016 → Dec 2026 expected | Parkinson disease, brain neoplasm, cognitive impairment with or without cerebellar ataxia, epilepsy +6 | Endeavor Health | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT02087865 Comparator | May 2014 → Dec 2021 | familial Alzheimer disease | The Cleveland Clinic | Completed | No outcome recorded |
| Phase 4 | NCT01849042 Background | Jan 2013 → Aug 2014 | Alzheimer disease | Konkuk University Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT03109314 Comparator | May 2012 → Dec 2018 | amblyopia | Dennis Levi | Completed | No outcome recorded |
| Phase 4 | NCT01490567 Comparator | Jun 2011 → Jun 2012 | schizophrenia | Central South University | Unknown | No outcome recorded |
| Phase 4 | NCT00619983 Comparator | Feb 2008 → May 2013 | chronic pain syndrome, diabetic neuropathy | Wake Forest University | Terminated | No outcome recorded |
| Phase 4 | NCT00866060 Comparator | Feb 2008 → Feb 2012 | Alzheimer disease | King's College London | Unknown | No outcome recorded |
| Phase 4 | NCT00711204 Comparator | Jan 2008 → Jun 2009 | Alzheimer disease | Eisai Inc. | Withdrawn | No outcome recorded |
| Phase 4 | NCT00505167 Comparator | Jul 2007 → Jul 2008 | Alzheimer disease | Hospital Miguel Servet | Completed | No outcome recorded |
| Phase 4 | NCT00465283 Comparator | May 2007 → Jan 2010 | schizoaffective disorder, schizophrenia, schizophreniform disorder | BeerYaakov Mental Health Center | Unknown | No outcome recorded |
| Phase 4 | NCT00768261 Comparator | Nov 2004 → Oct 2009 | dementia | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT01822951 Comparator | ? → Sep 2016 | Alzheimer disease | Ever Neuro Pharma GmbH | Withdrawn | No outcome recorded |
| Phase not applicable12 trials | ||||||
| — | NCT07351773 Background | Jan → Jun 2025 | Alzheimer disease | Taizhou Second People's Hospital | Completed | No outcome recorded |
| — | NCT06417086 Background | Jun 2024 → Nov 2026 expected | Alzheimer disease | ZhanYJ | Recruiting | No outcome recorded |
| — | NCT05078944 Background | Jun 2022 → Sep 2025 | Alzheimer disease type 1 | Shanghai Institute of Acupuncture, Moxibustion and Meridian | Completed | No outcome recorded |
| — | NCT05518409 Background | Apr 2022 → Dec 2023 | Alzheimer disease, Lewy body dementia | First Affiliated Hospital of Zhejiang University | Unknown | No outcome recorded |
| — | NCT04732182 Background | Feb → Dec 2022 | Alzheimer disease | Bright Cloud International Corp | Unknown | No outcome recorded |
| — | NCT04754152 Comparator | Apr 2021 → May 2022 | — | Anhui Medical University | Completed | No outcome recorded |
| — | NCT03810794 Background | Mar 2019 → Dec 2026 expected | Alzheimer disease, cognitive impairment with or without cerebellar ataxia | Jian Pei,MD | Recruiting | No outcome recorded |
| — | NCT05102045 Background | Sep 2016 → May 2017 | Alzheimer disease | Istanbul Medipol University Hospital | Completed | No outcome recorded |
| — | NCT02331771 Comparator | Sep 2015 → Jan 2017 | cognitive disorder | Porter Adventist Hospital | Terminated | No outcome recorded |
| — | NCT01738295 Comparator | Jan 2013 → Aug 2014 | — | University of Montreal | Completed | No outcome recorded |
| — | NCT00423228 Comparator | Feb 2007 → Apr 2009 | Alzheimer disease | Debiopharm International SA | Completed | No outcome recorded |
| — | NCT00467766 Background | Jul 1999 → Jun 2003 | Alzheimer disease | Pfizer | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2008-03-28 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Provides Update On Generic Aricept® Litigation tevapharm.com ↗ |
| 2008-01-14 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Tentative Approval Of Generic Aricept® Tablets tevapharm.com ↗ |
Evidence & citations 42 cited values
Every value below carries the sentence it was read from. 292 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | donepezil | “Battery of medications provided through a 12-week schedule including: Minocycline, Lamotrigine, Flumazenil, Modafinil, Bromocriptine, Donepezil, Methylphenidate, Methyl B12,...” NCT02696512 ↗256“This study compared the pharmacokinetic (PK) characteristics and safety profiles of an FDC formulation (donepezil/memantine [10/20 mg]) and single components (SCs) of donepezil...” PMID 40444644 ↗ May 2025 “Donepezil will be used at initial dose of 2.5 mg/day (during the first two weeks), and an increased dose of 5 mg/day (from the 3rd week and on), according to the treatment...” NCT01098383 ↗ “Compare the Efficacy and Safety of Donepezil Hydrochloride 23 mg Treatment With Continuation of Donepezil Hydrochloride 10 mg Treatment in Japanese Subjects With Severe...” NCT01539031 ↗ “A Phase 1, Randomized, Open-Label, Exploratory, Sequential, Pharmacokinetic Single Ascending Dose Study of IVL3003 Versus Multiple Doses of Aricept (Donepezil) Tablets in...” NCT05345509 ↗ “In titration period, donepezil 5-mg tablet will be taken orally once daily for 6 weeks, following donepezil 10 mg tablets taken orally once daily for 18 weeks in the maintenance period.” NCT01404169 ↗ “A 12-Week, Multicenter, Open-Label Study to Evaluate the Effectiveness and Safety of Donepezil Hydrochloride (Aricept) in Hispanic Patients With Mild to Moderate Alzheimer's Disease” NCT00230568 ↗ “Donepezil will then be added to duloxetine 120mg qam (or the highest dose the patient can tolerate if it is lower than 120mg) by 5mg qd for 1 week, followed by 10mg qd for 1 week.” NCT02857244 ↗ “Conventional anti-dementia treatment: Early-stage Alzheimer's disease (AD) patients routinely take cholinesterase inhibitors such as donepezil for treatment.” NCT07604896 ↗ “Patients in the medication group received only the currently recognized pharmacological treatments for AD, including Memantine Hydrochloride and Donepezil.” NCT07094438 ↗ “23 mg donepezil sustained release (SR) concurrently with placebo identical in appearance to the 10 mg donepezil immediate release (IR) formulation” NCT01276353 ↗ “The investigators will identify Veterans who have been taking a cholinesterase inhibitor (CI) (donepezil or galantamine) for at least one year.” NCT02248636 ↗ “Donepezil: Subjects will take 5 mg/day of donepezil in the evening for first 4 weeks, then 10 mg/day of donepezil in the evening until week 13.” NCT04318639 ↗ “Drug intervention group AD patients with drug regimen (donepezil 5mg / d) and primary care guidance, once every three months follow-up.” NCT04754152 ↗ “Levels of acetylcholine in the cerebral cortex will be enhanced by administration of donepezil, an inhibitor of acetylcholinesterase.” NCT05003063 ↗ “This study is to evaluate the safety and tolerability of single dose of GB-5001 (donepezil) IM and SC depot in healthy male Adults.” NCT06127368 ↗ “stable dose of cholinesterase inhibitor (donepezil, rivastigmine or galantamine) and/or memantine, as per standard practice.” NCT01872598 ↗ “GB-5001 is an intramuscular (IM) formulation of donepezil under development for the treatment of Alzheimer's disease.” PMID 39126603 ↗ Aug 2024 “with either galantamine hydrobromide (AChEI + nicotinic receptor modulation) or donepezil hydrochloride (AChEI only)” NCT00369603 ↗ “The Efficacy, Tolerability and Safety of Donepezil (Aricept) in Parkinson's Disease Patients With Dementia” NCT00165815 ↗ “Open-label donepezil tablets (dose strength: 10 mg) administered orally, QD on Days 1-14.” NCT03740178 ↗ “Donepezil, Rivastigmine, Galantamine were given in combination for Alzheimer's disease.” NCT05102045 ↗ “Cholinesterase inhibitors (donepezil, rivastigmine or galantamine) and/or memantine” NCT05564169 ↗ “mild cognitive impairment (donepezil, rivastigmine, memantine)” NCT02670161 ↗ “Drug: Donepezil Hydrochloride 10 mg orally for 12 months” NCT00403520 ↗ “7 days of 5 mg donepezil QD; 14 days 10 mg QD (Period 2)” NCT01097876 ↗ “Donepezil: 10 mg total daily dose, administered orally” NCT01852110 ↗ “Donepezil 10 mg Oral Tablet qd for 24 weeks” NCT03441516 ↗ “Oral Donepezil (5 mg QD for 6 Weeks)” NCT00483028 ↗ “Donepezil/Memantin Combination” NCT03954613 ↗ “Donepezil - 5 mg or 10 mg” NCT02035982 ↗ “solifenacin and donepezil” NCT02860065 ↗ |
| Known as | [14C]DONEPEZIL HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL502 ↗ |
| Known as | Adlarity | ChEMBL registry synonym — accepted as the source's own label CHEMBL502 ↗ |
| Known as | Aricept | “And, it is to predict the multiple-dose pharmacokinetics based on the single-dose pharmacokinetics of GB-5001 IM depot and the oral Aricept® (donepezil hydrochloride) tablet by...” NCT05525780 ↗40“A Phase 1, Randomized, Open-Label, Exploratory, Sequential, Pharmacokinetic Single Ascending Dose Study of IVL3003 Versus Multiple Doses of Aricept (Donepezil) Tablets in...” NCT05345509 ↗ “A 12-Week, Multicenter, Open-Label Study to Evaluate the Effectiveness and Safety of Donepezil Hydrochloride (Aricept) in Hispanic Patients With Mild to Moderate Alzheimer's Disease” NCT00230568 ↗ “Randomized, Open-Label, 2-Way Crossover, Bioequivalence Study of Donepezil 10 mg Tablet and Aricept® (Reference) Following a 10 mg Dose in Healthy Subjects Under Fasting Conditions” NCT01439230 ↗ “Participant takes 10 mg of Aricept daily or wears an Exelon 9.5 mg patch and is stable on one of these medications that were prescribed for diagnostic of early Alzheimer's Disease” NCT04732182 ↗ “The purpose of this study is to examine the efficacy and safety of cholinesterase inhibitor (donepezil hydrochloride) Aricept in patients with vascular dementia (VaD).” NCT00165763 ↗ “This is a 12-week, randomized, placebo controlled study to determine if donepezil (Aricept) treatment during rehabilitation after stroke improves functional recovery.” NCT00868010 ↗ “The purpose of this study is to evaluate the effectiveness of donepezil (Aricept) for the treatment of mild cognitive impairment (MCI) in elderly adults.” NCT00042172 ↗ “Participants are instructed to take one 5mg pill (donepezil HCL \[Aricept®\]) every night before going to bed with a glass of water for 28 days.” NCT01250977 ↗ “This study will evaluate the safety and effectiveness of donepezil (Aricept) for treating mild dementia in patients with Parkinson's disease.” NCT00030979 ↗ “This study will evaluate the effectiveness of donepezil (Aricept®) and cognitive training in improving memory performance in elderly adults.” NCT00043589 ↗ “Donepezil (Aricept) 5 mg tablet orally once daily for 30 days, followed by 10 mg tablet orally once daily to complete 6 months of treatment” NCT00630851 ↗ “Donepezil (also known as Aricept) has been FDA approved for improving memory and learning in individuals with Alzheimer's disease.” NCT00062972 ↗ “Donepezil hydrochloride (Aricept) has been approved to treat symptoms associated with mild to moderate Alzheimer's disease (AD).” NCT00096473 ↗ “Donepezil (Aricept), a cholinesterase inhibitor, is used clinically to ameliorate memory-related cognitive deficits.” PMID 29336496 ↗ Feb 2018 “Donepezil HCI (Aricept®) is an FDA-approved drug now used to enhance memory in patients with Alzheimer's disease.” NCT00315367 ↗ “Patients were randomized to receive placebo thrice daily, or octohydroaminoacridine 4 mg/TID or ARICEPT 5mg/QD.” NCT03283059 ↗ “Safety, Tolerability, and Efficacy of Donepezil (Aricept) in Parkinson' s Disease (PD) Patients With Dementia” NCT01327859 ↗ “The Efficacy, Tolerability and Safety of Donepezil (Aricept) in Parkinson's Disease Patients With Dementia” NCT00165815 ↗ “Aricept® Orally Disintegrating Tablets, Manufactured and Marketed by Eisai Inc.” NCT01260922 ↗ “Aricept® Orally Disintegrating Tablets, Manufactured and Marketed by Eisai Inc.” NCT01260948 ↗ “The substance donepezil (under the brand name Aricept®) is a resale product.” NCT06774261 ↗ “Drug-Drug Interaction Study With Aricept® (Donepezil)” NCT01042314 ↗ “Aricept (5 mg and 10 mg) Donepezil Hydrochloride” NCT02968719 ↗ “Aricept 5 mg (donepezil hydrochloride) drug” NCT05811000 ↗ “Aricept (donepezil hydrochloride)” NCT00754052 ↗ “Aricept (donepezil hydrochloride)” NCT01146509 ↗ “Aricept (Donepezil hydrochloride)” NCT00754013 ↗ “Donepezil Oral Tablet (Aricept®)” NCT06127368 ↗ “Aricept (donepezil SR 23 mg)” NCT00478205 ↗ “Donepezil (Aricept®)” NCT00768261 ↗ “Donepezil (Aricept)” NCT00467766 ↗ “Donepezil (Aricept)” NCT06903910 ↗ |
| Known as | ARICEPT Donépezil | “ARICEPT ® Donépezil” NCT01487395 ↗ |
| Known as | Aricept evess | ChEMBL registry synonym — accepted as the source's own label CHEMBL502 ↗ |
| Known as | Aricept odt | ChEMBL registry synonym — accepted as the source's own label CHEMBL502 ↗ |
| Known as | Aricept Tablet | “Aricept Tablet” NCT02968719 ↗ |
| Known as | Aricept(Registered Trademark) | “This study will test whether donepezil (Aricept(Registered Trademark)), a drug that is approved by the Food and Drug Administration to treat Alzheimer's disease” NCT00695136 ↗ |
| Known as | BNAG | ChEMBL registry synonym — accepted as the source's own label CHEMBL502 ↗ |
| Known as | Brand name for donepezil: Aricept | “Brand name for donepezil: Aricept” NCT00911807 ↗ |
| Known as | Corplex Donepezil TDS | “Corplex Donepezil TDS” NCT02968719 ↗ |
| Known as | D797 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03802162 ↗ |
| Known as | DKF-310 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02695004 ↗ |
| Known as | Donaz | ChEMBL registry synonym — accepted as the source's own label CHEMBL502 ↗ |
| Known as | donepezil (Aricept) | “donepezil (Aricept)” NCT00934531 ↗ |
| Known as | Donepezil (generic name) | “Donepezil (generic name)” NCT01439243 ↗1“Donepezil (generic name)” NCT01439230 ↗ |
| Known as | Donepezil Dihydroxynaphthalate | “A Single-center, Open-label, Single-dose Ascending Phase I Clinical Study Evaluating the Safety, Tolerability, and Pharmacokinetic Profile of HHT201 (Donepezil...” NCT06373094 ↗ |
| Known as | Donepezil HCI | “Donepezil HCI (Aricept®) is an FDA-approved drug now used to enhance memory in patients with Alzheimer's disease.” NCT00315367 ↗ |
| Known as | Donepezil HCl | “5 mg donepezil HCl given once a day and increased to 10 mg per day if side effects, when present, are tolerated.” NCT00165763 ↗4“donepezil HCL (a cholinesterase inhibitor)” NCT02087865 ↗ “Drug: Donepezil HCl” NCT00571064 ↗ “Drug: Donepezil HCl” NCT00570128 ↗ “Drug: Donepezil HCl” NCT00047697 ↗ |
| Known as | Donepezil Hydrochloride | “A 3-year, double-blind, placebo-controlled Alzheimer's Disease Cooperative Study initially designed to evaluate the efficacy of donepezil hydrochloride or vitamin E vs placebo...” PMID 17210817 ↗ Jan 200734“A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe...” NCT01404169 ↗ “And, it is to predict the multiple-dose pharmacokinetics based on the single-dose pharmacokinetics of GB-5001 IM depot and the oral Aricept® (donepezil hydrochloride) tablet by...” NCT05525780 ↗ “A 12-Week, Multicenter, Open-Label Study to Evaluate the Effectiveness and Safety of Donepezil Hydrochloride (Aricept) in Hispanic Patients With Mild to Moderate Alzheimer's Disease” NCT00230568 ↗ “This proposal is for a 6 to 20 week, single arm, open-label study to evaluate the ability of donepezil hydrochloride to enhance REM sleep in children with autism spectrum disorder” NCT00695136 ↗ “The purpose of this study is to examine the efficacy and safety of cholinesterase inhibitor (donepezil hydrochloride) Aricept in patients with vascular dementia (VaD).” NCT00165763 ↗ “Donepezil hydrochloride (Aricept) has been approved to treat symptoms associated with mild to moderate Alzheimer's disease (AD).” NCT00096473 ↗ “Donepezil Hydrochloride (E2020) In Subjects With Mild To Severe Alzheimer's Disease Residing In An Assisted Living Facility” NCT00571064 ↗ “The Evaluation of the Efficacy and Safety of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment (MCI)” NCT00293176 ↗ “with either galantamine hydrobromide (AChEI + nicotinic receptor modulation) or donepezil hydrochloride (AChEI only)” NCT00369603 ↗ “Donepezil hydrochloride tablets 5 mg, once a day, one tablet each time, before going to bed.” NCT05641480 ↗ “Pilot randomized trial of donepezil hydrochloride for delirium after hip fracture.” PMID 22091574 ↗ Nov 2011 “Donepezil Hydrochloride Transdermal Delivery System (5mg and 10 mg Version B)” NCT02968719 ↗ “Drug: Donepezil Hydrochloride 10 mg orally for 12 months” NCT00403520 ↗ “Test- Donepezil Hydrochloride 10 mg Tablet single dose” NCT01297036 ↗ “Aricept 5 mg (donepezil hydrochloride) drug” NCT05811000 ↗ “Donepezil Hydrochloride (Aricept®)” NCT00570128 ↗ “Donepezil hydrochloride (Aricept)” NCT00675025 ↗ “Donepezil Hydrochloride (Aricept)” NCT00711204 ↗ “Drug: donepezil hydrochloride” NCT00006349 ↗ “E2020-Donepezil hydrochloride” NCT02094053 ↗ “Drug: Donepezil Hydrochloride” NCT03151382 ↗ “Drug: Donepezil hydrochloride” NCT00688376 ↗ “Drug: Donepezil Hydrochloride” NCT03907371 ↗ |
| Known as | Donepezil Hydrochloride (generic name) | “Donepezil Hydrochloride (generic name)” NCT01260922 ↗ |
| Known as | Donepezil hydrochloride component of namzaric | ChEMBL registry synonym — accepted as the source's own label CHEMBL502 ↗ |
| Known as | DONEPEZIL HYDROCHLORIDE MONOHYDRATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL502 ↗ |
| Known as | Donepezil TDS | “Drug: Donepezil TDS” NCT03397862 ↗ |
| Known as | Donepezil TDS Version A | “Donepezil TDS Version A” NCT02968719 ↗ |
| Known as | Donepezil TDS Version B | “Donepezil TDS Version B” NCT02968719 ↗ |
| Known as | Donepezil TDS Version D | “Donepezil TDS Version D” NCT02968719 ↗ |
| Known as | Donepezil TDS Version E | “Donepezil TDS Version E” NCT02968719 ↗ |
| Known as | Donepezilo | ChEMBL registry synonym — accepted as the source's own label CHEMBL502 ↗ |
| Known as | donezepil | “You will receive Aricept for 5 weeks (donezepil)” NCT00031018 ↗ |
| Known as | E2020 | “A 24 Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Donepezil Hydrochloride (E2020) in Patients With Severe...” NCT00096473 ↗6“Donepezil Hydrochloride (E2020) In Subjects With Mild To Severe Alzheimer's Disease Residing In An Assisted Living Facility” NCT00571064 ↗ “Donepezil Hydrochloride (E2020)” NCT00165737 ↗ “E2020-Donepezil hydrochloride” NCT02094053 ↗ “Drug: E2020” NCT01404169 ↗ |
| Known as | E2022 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01253434 ↗ |
| Known as | GB-5001 | “This study is to evaluate the safety and tolerability of single dose of GB-5001 (donepezil) IM and SC depot in healthy male Adults.” NCT06127368 ↗1“GB-5001 is an intramuscular (IM) formulation of donepezil under development for the treatment of Alzheimer's disease.” PMID 39126603 ↗ Aug 2024 |
| Known as | IPI-301 | “the test drug, IPI-301 (donepezil transdermal patch), to the comparator, Aricept tablet” NCT03197740 ↗ |
| Known as | MK-4334 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03740178 ↗ |
| Known as | NSC-737535 | ChEMBL registry synonym — accepted as the source's own label CHEMBL502 ↗ |
| Known as | NSC-758882 | ChEMBL registry synonym — accepted as the source's own label CHEMBL502 ↗ |
| Action | Inhibit | “donepezil, an acetylcholinesterase inhibitor” NCT00030979 ↗1“Acetylcholinesterase inhibitor” CHEMBL502 ↗ |
| Modality | Small molecule | “Donepezil is a piperidine-based reversible, noncompetitive ChEI” NCT00190021 ↗ |
| Route | Oral | “Patients receive oral donepezil daily and vitamin E twice daily.” NCT00006349 ↗ |
| Target | ACHE | “Acetylcholinesterase inhibitor” CHEMBL502 ↗ |